Esperion Therapeutics (ESPR) Research & Development: 2018-2025
Historic Research & Development for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $14.1 million.
- Esperion Therapeutics' Research & Development rose 35.91% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 15.28%. This contributed to the annual value of $46.2 million for FY2024, which is 46.30% down from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Research & Development is $14.1 million, which was up 95.23% from $7.2 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Research & Development high stood at $33.0 million for Q4 2022, and its period low was $7.2 million during Q2 2025.
- Moreover, its 3-year median value for Research & Development was $13.4 million (2024), whereas its average is $15.1 million.
- Per our database at Business Quant, Esperion Therapeutics' Research & Development crashed by 57.29% in 2024 and then surged by 35.91% in 2025.
- Over the past 5 years, Esperion Therapeutics' Research & Development (Quarterly) stood at $27.6 million in 2021, then increased by 19.62% to $33.0 million in 2022, then slumped by 46.29% to $17.7 million in 2023, then tumbled by 38.13% to $11.0 million in 2024, then surged by 35.91% to $14.1 million in 2025.
- Its last three reported values are $14.1 million in Q3 2025, $7.2 million for Q2 2025, and $12.6 million during Q1 2025.